Featured

Oncology Data Advisor™ · Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this f...

ODACon 2022

Oncology Data Advisor™ invites you to attend this one-day virtual conference focusing on breast cancer. This virtual conference will provide expert perspectives on the mechanisms of action and efficacy/safety profiles of novel therapy classes, therap...

From the Editor's Desk

It's been a busy three months here at Oncology Data Advisor (ODA) since I last banged out an "Editor's Notes." One of the highlights was ODA's presence at the American Society of Clinical Oncology (ASCO) Annual Meeting. Many researchers spoke on camera with us about the work they were presenting at the meeting, and visibility for the website increased tremendously. It was a rousing success. I remain incredibly proud of all the hard work our staff does every day to bring the cutting edge of clini...



Copyright © 2022 Oncology Data Advisor. All rights reserved.